Indivior PLC (NASDAQ:INDV – Get Free Report) CAO Woodrow Anderson acquired 1,500 shares of Indivior stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the completion of the purchase, the chief accounting officer directly owned 27,638 shares of the company’s stock, valued at approximately $986,400.22. The trade was a 5.74% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.
Indivior Trading Down 1.2%
NASDAQ INDV opened at $34.87 on Friday. Indivior PLC has a 1-year low of $22.22 and a 1-year high of $42.81. The stock has a 50-day moving average of $39.33 and a 200-day moving average of $36.00. The firm has a market cap of $4.12 billion, a PE ratio of 12.50 and a beta of 0.86.
Indivior (NASDAQ:INDV – Get Free Report) last posted its quarterly earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share (EPS) for the quarter. The business had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. As a group, equities research analysts forecast that Indivior PLC will post 3.66 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Indivior
Analyst Upgrades and Downgrades
Several research analysts recently commented on the stock. Barclays decreased their target price on shares of Indivior from $46.00 to $43.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, August 21st. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Craig Hallum restated a “buy” rating and issued a $53.00 price objective on shares of Indivior in a research report on Tuesday, August 4th. Five research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, Indivior presently has an average rating of “Moderate Buy” and a consensus target price of $45.17.
Check Out Our Latest Stock Analysis on INDV
Indivior Company Profile
Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.
Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.
Featured Articles
- Five stocks we like better than Indivior
- 3 Financial Stocks Positioned for the Fed’s Next Move After Jackson Hole
- IREN’s AI Pivot Looks Real, But the Market Wanted a Faster Payoff After Earnings
- Boeing’s $131B F-15 Win: Mach 1 Momentum or Just Altitude?
- Okta Stock Surges 29%—Is $200 the Next Stop?
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
